Interview: Izana Tests GM-CSF Drug For Coronavirus
Compassionate Use Study Of Namilumab Starts In Italy
Executive Summary
The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.
You may also be interested in...
GSK's Otilimab Goes Head-To-Head To Crack Rheumatoid Arthritis
GlaxoSmithKline is exploring a potential new way of tackling rheumatoid arthritis in just-started Phase III studies which could shake up a disease sector that is already attracting interest from other big pharma companies.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.